Advertisement
Canada markets open in 7 hours 44 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7305
    +0.0007 (+0.10%)
     

  • CRUDE OIL

    82.96
    +0.15 (+0.18%)
     

  • Bitcoin CAD

    88,004.62
    -3,351.54 (-3.67%)
     

  • CMC Crypto 200

    1,386.29
    -37.81 (-2.66%)
     

  • GOLD FUTURES

    2,329.60
    -8.80 (-0.38%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,433.75
    -230.75 (-1.31%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,649.89
    -810.19 (-2.11%)
     

  • CAD/EUR

    0.6817
    -0.0002 (-0.03%)
     

Today's Research Reports on Trending Tickers: Clovis Oncology and Global Blood Therapeutics

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / July 4, 2018 /

U.S. equities dropped on Tuesday, as gains in energy, real-estate and telecom shares were offset by losses in tech and financial names. The Dow Jones Industrial Average decreased 0.54 percent to close at 24,174.82, while the S&P 500 Index shed 0.49 percent to close at 2,713.22. The Nasdaq Composite Index have fallen 0.49 percent to close at 7,502.67.

Managing director of sales and trading at Themis Trading, Mark Kepner said, “There is not much pure information that would be moving the market, but when trading volumes are low, like today, any piece of news can exaggerate moves.”

RDI Initiates Coverage on:

Clovis Oncology, Inc.
https://rdinvesting.com/news/?ticker=CLVS

ADVERTISEMENT

Global Blood Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=GBT

Clovis Oncology's stock jumped 5.01% Tuesday, to close the day at $47.40. The stock recorded a trading volume of 570,325 shares, which was below its three months average volume of 1,320,700 shares. In the last year, Clovis Oncology's shares have traded in a range of 41.31 - 99.45. The share price has gained 14.74% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $47.06 is below its 200-day moving average of $54.18. Shares of Clovis Oncology have fallen roughly 0.69 percent in the past month and are down 30.29 percent year-to-date.

Access RDI's Clovis Oncology, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CLVS

On Tuesday, shares of Global Blood Therapeutics recorded a trading volume of 1,224,440 shares, which was above the three months average volume of 1,138,340 shares. The stock ended the day 4.78% higher at $44.95. The share price has fallen 33.95% from its 52 week high with a 52 week trading range of 24.02 - 68.05. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $45.88 is below its 200-day moving average of $49.58. Shares of Global Blood Therapeutics have fallen roughly 9.65 percent in the past month and are up 14.23 percent year-to-date.

Access RDI's Global Blood Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GBT

Our Actionable Research on Clovis Oncology, Inc. (NASDAQ:CLVS) and Global Blood Therapeutics, Inc. (NASDAQ:GBT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email: contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com